Risankizumab (AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin (IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23. It is being developed in psoriasis and Crohn’s disease.
LIST OF FIGURES
13 Figure 22: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
16 Figure 14: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
24 Figure 24: Datamonitor Healthcare’s drug assessment summary of Seebri Neohaler for COPD
LIST OF TABLES
5 Table 1: Risankizumab drug profile
7 Table 2: Risankizumab Phase III trials in Crohn’s disease
11 Table 3: Risankizumab Phase II data in Crohn’s disease
17 Table 4: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
20 Table 5: Risankizumab drug profile
21 Table 6: Risankizumab late-phase trials in psoriasis
22 Table 7: Phase II results from risankizumab’s head-to-head trial against Stelara
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726